Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
A. Pauchet, A. Chaussavoine, JC Pairon, C. Gabillon, A. Didier, I. Baldi & Y. Esquirol. (2022) Idiopathic Pulmonary Fibrosis: What do we Know about the Role of Occupational and Environmental Determinants? A Systematic Literature Review and Meta-Analysis. Journal of Toxicology and Environmental Health, Part B 25:7, pages 372-392.
Read now
Read now
Vadivel Dinesh Babu, Anandasadagopan Suresh Kumar & Ganapasam Sudhandiran. (2022) Diosgenin inhibits TGF-β1/Smad signaling and regulates epithelial mesenchymal transition in experimental pulmonary fibrosis. Drug and Chemical Toxicology 45:3, pages 1264-1275.
Read now
Read now
Min Qiu, Zheng Yang, Mengni Bian, Changxiao Liu, Yunshan Zhao & Quanli Liu. (2020) Protective effects of isorhynchophylline against silicon-dioxide-induced lung injury in mice. Artificial Cells, Nanomedicine, and Biotechnology 48:1, pages 1125-1134.
Read now
Read now
Riccardo Inchingolo, Carola Condoluci, Andrea Smargiassi, Annelisa Mastrobattista, Cristina Boccabella, Alessia Comes, Nicoletta Golfi & Luca Richeldi. (2017) Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?. Expert Opinion on Pharmacotherapy 18:15, pages 1583-1594.
Read now
Read now
Tatjana S. Sarenac Vulovic, Sladjana M. Pavlovic & Nemanja S. Zdravkovic. (2016) Proinflammatory Cytokines Induce XFG Development. Ocular Immunology and Inflammation 24:6, pages 671-677.
Read now
Read now
Xinjun Zhao, Yue Hua, Hongmei Chen, Haiyu Yang, Tao Zhang, Guiqiong Huang, Huijie Fan, Zhangbin Tan, Xiaofang Huang, Bin Liu & Yingchun Zhou. (2015) Aldehyde dehydrogenase-2 protects against myocardial infarction-related cardiac fibrosis through modulation of the Wnt/β-catenin signaling pathway. Therapeutics and Clinical Risk Management 11, pages 1371-1381.
Read now
Read now
Francesco Bonella, Susanne Stowasser & Lutz Wollin. (2015) Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Design, Development and Therapy 9, pages 6407-6419.
Read now
Read now
Articles from other publishers (12)
Ladan Panahi, George Udeani, Andrew Scott Tenpas, Theresa Ofili, Elizabeth Marie Aguilar, Sarah Burchard, Alexandra Ruth Ritenour, April Jacob Chennat, Nehal Ahmed, Chairat Atphaisit, Crystal Chi, Jesus Cruz III, Monica D. Deleon, Samantha Lee, Zack Mayo, Mackenzie Mcbeth, Mariel Morales, Jennifer N. Nwosu, Kelly Palacios, Jaycob M. Pena & Nitza Vara. 2022. Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis.
Shengnan Yang, Peipei Liu, Yale Jiang, Zai Wang, Huaping Dai & Chen Wang. (2021) Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Mitra Corral, Eunice Chang, Michael S Broder, Sohum Gokhale & Sheila R Reddy. (2020) Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis. Journal of Comparative Effectiveness Research 9:13, pages 933-943.
Crossref
Crossref
Andrew Rasky, David M. Habiel, Susan Morris, Matthew Schaller, Bethany B. Moore, Sem Phan, Steven L. Kunkel, Martin Phillips, Cory Hogaboam & Nicholas W. Lukacs. (2020) Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease. American Journal of Physiology-Lung Cellular and Molecular Physiology 318:1, pages L200-L211.
Crossref
Crossref
M.I. Gumeniuk. (2019) Comorbid Metabolic Disorders in Chronic Lung Diseases. Infusion & Chemotherapy:3, pages 5-15.
Crossref
Crossref
Argyrios Tzouvelekis, Rebecca Toonkel, Theodoros Karampitsakos, Kantha Medapalli, Ioanna Ninou, Vasilis Aidinis, Demosthenes Bouros & Marilyn K. Glassberg. (2018) Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Frontiers in Medicine 5.
Crossref
Crossref
Ourania Papaioannou, Theodoros Karampitsakos, Ilianna Barbayianni, Serafeim Chrysikos, Nikos Xylourgidis, Vasilis Tzilas, Demosthenes Bouros, Vasilis Aidinis & Argyrios Tzouvelekis. (2018) Metabolic Disorders in Chronic Lung Diseases. Frontiers in Medicine 4.
Crossref
Crossref
Eva Brunnemer, Julia Wälscher, Svenja Tenenbaum, Julia Hausmanns, Karen Schulze, Marianne Seiter, Claus Peter Heussel, Arne Warth, Felix J.F. Herth & Michael Kreuter. (2018) Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Respiration 95:5, pages 301-309.
Crossref
Crossref
Argyrios Tzouvelekis, Theodoros Karampitsakos, Paschalis Ntolios, Vasilios Tzilas, Evangelos Bouros, Evangelos Markozannes, Ioanna Malliou, Aris Anagnostopoulos, Andreas Granitsas, Paschalis Steiropoulos, Katerina Dimakou, Serafeim Chrysikos, Nikolaos Koulouris & Demosthenes Bouros. (2017) Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Frontiers in Medicine 4.
Crossref
Crossref
Xiaohong Li, Shaojie Yue & Ziqiang Luo. (2017) Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget 8:60, pages 102600-102616.
Crossref
Crossref
Jun Tashiro, Gustavo A. Rubio, Andrew H. Limper, Kurt Williams, Sharon J. Elliot, Ioanna Ninou, Vassilis Aidinis, Argyrios Tzouvelekis & Marilyn K. Glassberg. (2017) Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Frontiers in Medicine 4.
Crossref
Crossref
Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Martin J. Kohlhaeufl, Joachim Müller-Quernheim, Katrin Milger & Antje Prasse. (2016) Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration 92:2, pages 98-106.
Crossref
Crossref